AT320149B - Verfahren zur Herstellung eines attenuierten, modifizierten Pockenschutzimpfstoffes - Google Patents
Verfahren zur Herstellung eines attenuierten, modifizierten PockenschutzimpfstoffesInfo
- Publication number
- AT320149B AT320149B AT771172A AT771172A AT320149B AT 320149 B AT320149 B AT 320149B AT 771172 A AT771172 A AT 771172A AT 771172 A AT771172 A AT 771172A AT 320149 B AT320149 B AT 320149B
- Authority
- AT
- Austria
- Prior art keywords
- attenuated
- preparation
- smallpox vaccine
- modified
- modified smallpox
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/275—Poxviridae, e.g. avipoxvirus
- A61K39/285—Vaccinia virus or variola virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19712145477 DE2145477C3 (de) | 1971-09-11 | Impfstoff für die intracutane Pockenschutzimpfung |
Publications (1)
Publication Number | Publication Date |
---|---|
AT320149B true AT320149B (de) | 1975-01-27 |
Family
ID=5819271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT771172A AT320149B (de) | 1971-09-11 | 1972-09-08 | Verfahren zur Herstellung eines attenuierten, modifizierten Pockenschutzimpfstoffes |
Country Status (5)
Country | Link |
---|---|
AT (1) | AT320149B (de) |
BE (1) | BE787901A (de) |
CH (1) | CH568392A5 (de) |
DK (1) | DK137392C (de) |
ES (1) | ES406590A1 (de) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2714665A1 (de) * | 1977-04-01 | 1978-10-05 | Mayr Anton | Praeparat zur behandlung von herpes zoster und anderen herpes-infektionen, sowie verfahren zu seiner herstellung |
JPS60202827A (ja) * | 1984-03-28 | 1985-10-14 | Chibaken | 弱毒痘そうワクチン株 |
CA1341245C (en) * | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
ATE504653T1 (de) | 2002-08-07 | 2011-04-15 | Bavarian Nordic As | Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren |
EP2371380A1 (de) | 2003-03-28 | 2011-10-05 | The Government of the United States of America, represented by The Secretary, Department of Health and Human Services | MVA Virus, der modifizierte HIV hülle, gag und pol gene exprimiert |
DK1789438T3 (en) | 2004-08-27 | 2015-07-20 | Us Government | Recombinant MVA viruses expressing MODIFIED env, gag and pol genes of HIV CLADE A / G, CLADE CLADE B AND C |
WO2008138533A1 (en) | 2007-05-14 | 2008-11-20 | Bavarian Nordic A/S | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
KR20120093941A (ko) | 2009-10-08 | 2012-08-23 | 버베리안 노딕 에이/에스 | 인간에서 hiv에 대한 광범위한 t-세포 반응의 생성 |
WO2012010280A1 (en) | 2010-07-20 | 2012-01-26 | Bavarian Nordic A/S | Method for harvesting expression products |
EP2620446A1 (de) | 2012-01-27 | 2013-07-31 | Laboratorios Del Dr. Esteve, S.A. | Immunogene zur HIV-Impfung |
DE102013004595A1 (de) | 2013-03-15 | 2014-09-18 | Emergent Product Development Germany Gmbh | RSV-Impfstoffe |
CN109071592B (zh) | 2016-01-08 | 2022-07-19 | 吉奥瓦科斯公司 | 用于产生对肿瘤相关抗原的免疫应答的组合物和方法 |
WO2021094984A1 (en) | 2019-11-14 | 2021-05-20 | Aelix Therapeutics, S.L. | Dosage regimens for vaccines |
EP3928789A1 (de) | 2020-06-24 | 2021-12-29 | Consejo Superior de Investigaciones Científicas (CSIC) | Mva-basierter impfstoff gegen covid-19 exprimierende sars-cov-2-antigene |
WO2021260065A1 (en) | 2020-06-24 | 2021-12-30 | Consejo Superior De Investigaciones Científicas (Csic) | Mva-based vaccine against covid-19 expressing sars-cov-2 antigens |
EP4108257A1 (de) | 2021-06-23 | 2022-12-28 | Consejo Superior De Investigaciones Científicas | Impfstoff auf mva-basis gegen covid-19, der ein präfusionsstabilisiertes sars-cov-2-s-protein exprimiert |
EP4358999A1 (de) | 2021-06-23 | 2024-05-01 | Consejo Superior De Investigaciones Científicas | Mva-basierter impfstoff zur expression eines präfusionsstabilisierten sars-cov-2s-proteins |
-
1972
- 1972-08-23 BE BE787901A patent/BE787901A/xx unknown
- 1972-09-08 CH CH1297272A patent/CH568392A5/xx not_active IP Right Cessation
- 1972-09-08 AT AT771172A patent/AT320149B/de not_active IP Right Cessation
- 1972-09-11 ES ES406590A patent/ES406590A1/es not_active Expired
- 1972-09-11 DK DK447972A patent/DK137392C/da active
Also Published As
Publication number | Publication date |
---|---|
DE2145477B2 (de) | 1976-04-01 |
DE2145477A1 (de) | 1973-03-15 |
DK137392C (da) | 1978-09-18 |
DK137392B (da) | 1978-02-27 |
ES406590A1 (es) | 1975-09-16 |
BE787901A (fr) | 1972-12-18 |
CH568392A5 (de) | 1975-10-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AT320149B (de) | Verfahren zur Herstellung eines attenuierten, modifizierten Pockenschutzimpfstoffes | |
AT315829B (de) | Verfahren zur Herstellung von 4-Halogenmethylcumarinen | |
AT317435B (de) | Verfahren zur Herstellung eines antiseborrhoisch wirksamen Mittels | |
AT309679B (de) | Verfahren zur Herstellung von 6-Desoxytetracyclinen | |
AT326827B (de) | Verfahren zur herstellung eines pharmazeutischen eisenpräparates | |
AT324553B (de) | Verfahren zur herstellung von 3-alkylthiomethylcephalosporinen | |
AT316560B (de) | Verfahren zur Herstellung von 2,4-Diamino-5-benzylpyrimidinen | |
AT332538B (de) | Verfahren zur herstellung eines 7beta-aminocephalosporins | |
AT318823B (de) | Verfahren zur Herstellung von 16-Carboxy-17-methoxy-eburnan | |
DD101403A5 (de) | Verfahren zur herstellung von phenylimidazolidinonen | |
CH557803A (de) | Verfahren zur herstellung von o-sulfamylamidobenzoesaeuren. | |
AT305963B (de) | Verfahren zur Herstellung von N,O-Dialkylhydroxylaminen | |
AT327910B (de) | Verfahren zur herstellung von 5-acyl-iminostilben-derivaten | |
CH547797A (de) | Verfahren zur herstellung von n - ((1-aethyl-pyrrolidinyl2)-methyl) -2-methoxy-5-sulfamoyl-benzamid. | |
AT326816B (de) | Verfahren zur herstellung von 3-carbamoyloxymethylcephalosporinverbindungen | |
CH543571A (de) | Verfahren zur Herstellung von 3,10-Dichlorchinacridon | |
CH556332A (de) | Verfahren zur herstellung eines derivates des kasugamycins. | |
AT315191B (de) | Verfahren zur Herstellung von Arylsulfonylharnstoffen | |
CH528533A (de) | Verfahren zur Herstellung von Thiazylharnstoffen | |
AT317854B (de) | Verfahren zur Herstellung eines Ammoxidationskatalysators | |
CH547262A (de) | Verfahren zur herstellung von n-(diaethylaminoaethyl)-2methoxy-4-amino-5-chlor-benzamid. | |
CH557329A (de) | Verfahren zur herstellung von n-isopropylanilin. | |
CH556836A (de) | Verfahren zur herstellung von 1-alkenyl-2-aminomethylpyrrolidinen. | |
CH552658A (de) | Verfahren zur herstellung anthrachinoider dispersionsfarbstoffe. | |
AT321319B (de) | Verfahren zur Herstellung von Derivaten von Hydroxylverbindungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EIH | Change in the person of patent owner | ||
ELJ | Ceased due to non-payment of the annual fee |